Uyl-de Groot CA - Search Results

1

Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).

Uyl-de Groot CA, Hagenbeek A, Verdonck LF, Löwenberg B, Rutten FF. Uyl-de Groot CA, et al. Bone Marrow Transplant. 1995 Sep;16(3):463-70. Bone Marrow Transplant. 1995. PMID: 8535321 Clinical Trial.

2

The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.

Uyl-de Groot CA, Ossenkoppele GJ, van Riet AA, Rutten FF. Uyl-de Groot CA, et al. Eur J Cancer. 1994;30A(4):457-9. doi: 10.1016/0959-8049(94)90418-9. Eur J Cancer. 1994. PMID: 7517149 Free article.

3

Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation.

Uyl-de Groot CA, Richel DJ, Rutten FF. Uyl-de Groot CA, et al. Eur J Cancer. 1994;30A(11):1631-5. doi: 10.1016/0959-8049(94)00328-3. Eur J Cancer. 1994. PMID: 7530471

4

Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands.

Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, Huijgens PC, van Imhoff GW, Löwenberg B, Verdonck LF, Rutten FF. Uyl-de Groot CA, et al. Bone Marrow Transplant. 1995 Apr;15(4):605-10. Bone Marrow Transplant. 1995. PMID: 7655388

5

Measurement and valuation of quality of life in economic appraisal of cancer treatment.

Uyl-de Groot CA, Rutten FF, Bonsel GJ. Uyl-de Groot CA, et al. Eur J Cancer. 1994;30A(1):111-7. doi: 10.1016/s0959-8049(05)80030-9. Eur J Cancer. 1994. PMID: 8142152

6

[Costs of autologous bone marrow transplantation in non-Hodgkin lymphoma and acute leukemia].

Uyl-de Groot CA, Rutten FF. Uyl-de Groot CA, et al. Ned Tijdschr Geneeskd. 1994 Jan 1;138(1):28-31. Ned Tijdschr Geneeskd. 1994. PMID: 8289955 Dutch.

7

Economic evaluation alongside cancer trials: methodological and practical aspects.

Bonsel GJ, Rutten FF, Uyl-de Groot CA. Bonsel GJ, et al. Eur J Cancer. 1993;29A Suppl 7:S10-4. doi: 10.1016/0959-8049(93)90610-r. Eur J Cancer. 1993. PMID: 8312059

8

Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia.

Vellenga E, Uyl-de Groot CA, de Wit R, Keizer HJ, Löwenberg B, ten Haaft MA, de Witte TJ, Verhagen CA, Stoter GJ, Rutten FF, Mulder NH, Smid WM, de Vries EG. Vellenga E, et al. J Clin Oncol. 1996 Feb;14(2):619-27. doi: 10.1200/JCO.1996.14.2.619. J Clin Oncol. 1996. PMID: 8636779 Free article. Clinical Trial.

9

An economic model to assess the savings from a clinical application of haematopoietic growth factors.

Uyl-de Groot CA, Vellenga E, Rutten FF. Uyl-de Groot CA, et al. Eur J Cancer. 1996 Jan;32A(1):57-62. doi: 10.1016/0959-8049(95)00468-8. Eur J Cancer. 1996. PMID: 8695242

10

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

Uyl-de Groot CA, Löwenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Uyl-de Groot CA, et al. Br J Haematol. 1998 Mar;100(4):629-36. doi: 10.1046/j.1365-2141.1998.00635.x. Br J Haematol. 1998. PMID: 9531327 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters